PT2802606T - Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica - Google Patents
Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálicaInfo
- Publication number
- PT2802606T PT2802606T PT137025292T PT13702529T PT2802606T PT 2802606 T PT2802606 T PT 2802606T PT 137025292 T PT137025292 T PT 137025292T PT 13702529 T PT13702529 T PT 13702529T PT 2802606 T PT2802606 T PT 2802606T
- Authority
- PT
- Portugal
- Prior art keywords
- enhancement
- transport
- brain barrier
- blood brain
- therapeutic molecules
- Prior art date
Links
- 230000008499 blood brain barrier function Effects 0.000 title 1
- 210000001218 blood-brain barrier Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261585039P | 2012-01-10 | 2012-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2802606T true PT2802606T (pt) | 2018-07-13 |
Family
ID=47633561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT137025292T PT2802606T (pt) | 2012-01-10 | 2013-01-10 | Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica |
Country Status (25)
Country | Link |
---|---|
US (1) | US9676849B2 (pt) |
EP (1) | EP2802606B1 (pt) |
JP (1) | JP6247226B2 (pt) |
KR (1) | KR102104686B1 (pt) |
CN (1) | CN104159922B (pt) |
AU (1) | AU2013207927B2 (pt) |
BR (1) | BR112014016887A2 (pt) |
CA (1) | CA2860579A1 (pt) |
CY (1) | CY1120419T1 (pt) |
DK (1) | DK2802606T3 (pt) |
EA (1) | EA201491346A1 (pt) |
ES (1) | ES2677111T3 (pt) |
HK (1) | HK1203977A1 (pt) |
HR (1) | HRP20180937T1 (pt) |
HU (1) | HUE039033T2 (pt) |
IL (1) | IL233246B (pt) |
LT (1) | LT2802606T (pt) |
MX (1) | MX350378B (pt) |
NZ (1) | NZ626620A (pt) |
PL (1) | PL2802606T3 (pt) |
PT (1) | PT2802606T (pt) |
SI (1) | SI2802606T1 (pt) |
TR (1) | TR201809743T4 (pt) |
WO (1) | WO2013106577A2 (pt) |
ZA (1) | ZA201404873B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104428006B (zh) | 2012-07-04 | 2017-09-08 | 弗·哈夫曼-拉罗切有限公司 | 共价连接的抗原‑抗体缀合物 |
JP6521464B2 (ja) | 2014-01-03 | 2019-05-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 共有結合で連結されたポリペプチド毒素−抗体コンジュゲート |
RU2694981C2 (ru) | 2014-01-03 | 2019-07-18 | Ф. Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |
EP3960768A1 (en) * | 2014-01-03 | 2022-03-02 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
MX2016011561A (es) * | 2014-03-06 | 2017-04-13 | Nat Res Council Canada | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. |
UA120048C2 (uk) * | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
MX2016011557A (es) * | 2014-03-06 | 2017-04-13 | Nat Res Council Canada | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. |
JP6391318B2 (ja) * | 2014-06-27 | 2018-09-19 | 学校法人順天堂 | アルツハイマー病予防治療薬のスクリーニング法 |
EP3233922B1 (en) * | 2014-12-19 | 2022-05-11 | MedImmune Limited | Blood brain barrier transport molecules and uses thereof |
JP6986967B2 (ja) | 2015-01-29 | 2021-12-22 | テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー | アルツハイマー病及び関連障害に使用するための抗体分子及びペプチド送達システム |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
US10738115B2 (en) * | 2016-07-06 | 2020-08-11 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CA3046906A1 (en) | 2016-12-12 | 2018-06-21 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
KR102676279B1 (ko) * | 2017-01-30 | 2024-06-20 | 내션얼 리서치 카운슬 오브 캐나다 | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 |
EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
US11905327B2 (en) * | 2017-12-28 | 2024-02-20 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
CA3089279A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
JP2021529516A (ja) * | 2018-06-18 | 2021-11-04 | アンウィタ バイオサイエンシス, インク. | サイトカイン融合タンパク質及びその使用 |
US20210161993A1 (en) * | 2018-09-12 | 2021-06-03 | Pvp Labs Pte. Ltd. | Method for accelerated healing of burn wounds |
CA3115071A1 (en) | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
MA54070A (fr) * | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
AU2021476277A1 (en) * | 2021-12-02 | 2024-06-06 | Linno Pharmaceuticals Inc. | Transferrin binding antibodies and use thereof |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1166947A (en) | 1914-10-05 | 1916-01-04 | Paramount Hosiery Form Drying Company | Hosiery-finishing apparatus. |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
DE3751908T2 (de) | 1986-07-07 | 1997-02-06 | Centocor Inc | Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen |
NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH04505260A (ja) | 1989-05-22 | 1992-09-17 | ザイモジェネティクス,インコーポレイティド | PDGFα―受容体 |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
CA2102224A1 (en) | 1991-04-19 | 1992-10-20 | Toshio Kitamura | Human interleukin-3-receptor component |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
DE69628652T3 (de) | 1995-09-08 | 2012-05-03 | Genentech, Inc. | Vegf-verwandtes protein |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
DK0922102T3 (da) | 1996-07-03 | 2010-08-16 | Genentech Inc | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
EP0941120A4 (en) | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
IL143834A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
EP1328626B1 (en) * | 2000-05-26 | 2013-04-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US8039588B2 (en) | 2004-05-21 | 2011-10-18 | The Uab Research Foundation | Variable lymphocyte receptors |
CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
WO2007036022A1 (en) | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Targeted delivery of compounds using multimerization technology |
AU2007215013A1 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
WO2008143954A2 (en) * | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
MA34025B1 (fr) * | 2010-03-03 | 2013-02-01 | Boehringer Ingelheim Int | Polypeptides se liant au bêta-a |
EP2558503B1 (en) * | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Compositions and methods for brain delivery of analgesic peptides |
-
2013
- 2013-01-10 AU AU2013207927A patent/AU2013207927B2/en not_active Ceased
- 2013-01-10 DK DK13702529.2T patent/DK2802606T3/en active
- 2013-01-10 US US14/370,828 patent/US9676849B2/en active Active
- 2013-01-10 HU HUE13702529A patent/HUE039033T2/hu unknown
- 2013-01-10 CA CA2860579A patent/CA2860579A1/en active Pending
- 2013-01-10 EP EP13702529.2A patent/EP2802606B1/en active Active
- 2013-01-10 WO PCT/US2013/021041 patent/WO2013106577A2/en active Application Filing
- 2013-01-10 LT LTEP13702529.2T patent/LT2802606T/lt unknown
- 2013-01-10 EA EA201491346A patent/EA201491346A1/ru unknown
- 2013-01-10 MX MX2014008365A patent/MX350378B/es active IP Right Grant
- 2013-01-10 TR TR2018/09743T patent/TR201809743T4/tr unknown
- 2013-01-10 SI SI201331060T patent/SI2802606T1/en unknown
- 2013-01-10 NZ NZ626620A patent/NZ626620A/en unknown
- 2013-01-10 ES ES13702529.2T patent/ES2677111T3/es active Active
- 2013-01-10 PT PT137025292T patent/PT2802606T/pt unknown
- 2013-01-10 BR BR112014016887A patent/BR112014016887A2/pt not_active Application Discontinuation
- 2013-01-10 PL PL13702529T patent/PL2802606T3/pl unknown
- 2013-01-10 KR KR1020147018724A patent/KR102104686B1/ko active IP Right Grant
- 2013-01-10 JP JP2014552303A patent/JP6247226B2/ja active Active
- 2013-01-10 CN CN201380004989.7A patent/CN104159922B/zh active Active
-
2014
- 2014-06-19 IL IL233246A patent/IL233246B/en active IP Right Grant
- 2014-07-01 ZA ZA2014/04873A patent/ZA201404873B/en unknown
-
2015
- 2015-05-11 HK HK15104429.6A patent/HK1203977A1/xx unknown
-
2018
- 2018-06-18 HR HRP20180937TT patent/HRP20180937T1/hr unknown
- 2018-07-11 CY CY20181100721T patent/CY1120419T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013106577A2 (en) | 2013-07-18 |
WO2013106577A3 (en) | 2013-11-21 |
MX350378B (es) | 2017-09-05 |
IL233246B (en) | 2018-07-31 |
ES2677111T3 (es) | 2018-07-30 |
US20150210762A1 (en) | 2015-07-30 |
KR102104686B1 (ko) | 2020-04-24 |
PL2802606T3 (pl) | 2018-09-28 |
DK2802606T3 (en) | 2018-06-25 |
HK1203977A1 (en) | 2015-11-06 |
JP6247226B2 (ja) | 2017-12-13 |
KR20140112497A (ko) | 2014-09-23 |
TR201809743T4 (tr) | 2018-07-23 |
US9676849B2 (en) | 2017-06-13 |
LT2802606T (lt) | 2018-10-10 |
EP2802606B1 (en) | 2018-04-25 |
CN104159922A (zh) | 2014-11-19 |
MX2014008365A (es) | 2014-10-06 |
AU2013207927B2 (en) | 2017-11-02 |
ZA201404873B (en) | 2018-12-19 |
CY1120419T1 (el) | 2019-07-10 |
IL233246A0 (en) | 2014-08-31 |
JP2015509097A (ja) | 2015-03-26 |
CN104159922B (zh) | 2018-03-02 |
HRP20180937T1 (hr) | 2018-08-10 |
NZ626620A (en) | 2016-07-29 |
AU2013207927A1 (en) | 2014-07-17 |
BR112014016887A2 (pt) | 2018-08-14 |
CA2860579A1 (en) | 2013-07-18 |
EP2802606A2 (en) | 2014-11-19 |
HUE039033T2 (hu) | 2018-12-28 |
EA201491346A1 (ru) | 2014-11-28 |
SI2802606T1 (en) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203977A1 (en) | Enhancement of transport of therapeutic molecules across the blood brain barrier | |
HRP20190046T1 (hr) | Kombinirana terapija za liječenje raka | |
IL239084A0 (en) | Devices to support medical care | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
IL261659A (en) | Brain cancer treatment | |
EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
EP2830633A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
GB201207543D0 (en) | Treatment of transfusion blood | |
HUE039650T2 (hu) | Rendszer gyógykezeléshez | |
PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
EP2869796A4 (en) | PATIENT TREATMENT SYSTEM | |
HK1207984A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
IL233495A0 (en) | Combination for cancer treatment | |
GB201204645D0 (en) | Treatment of disease | |
GB201214454D0 (en) | Therapeutic treatments | |
GB201214456D0 (en) | Therapeutic treatments |